Stock data
Relmada Therapeutics, Inc. (RLMD)
Relmada Therapeutics, Inc. (RLMD) reported net income of -US$57.39M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$59.10M | -US$57.39M | — |
| 2024 | — | — | -US$83.89M | -US$79.98M | — |
| 2023 | — | — | -US$103.70M | -US$98.79M | — |
| 2022 | — | — | -US$161.25M | -US$157.04M | — |
| 2021 | — | — | -US$125.70M | -US$125.75M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$12.91M | — |
| 2026-03-31 | — | -US$19.05M | — |
| 2025-12-31 | — | -US$19.87M | — |
| 2025-09-30 | — | -US$10.09M | — |
| 2025-06-30 | — | -US$9.87M | — |
| 2025-03-31 | — | -US$17.56M | — |
| 2024-12-31 | — | -US$18.66M | — |
| 2024-09-30 | — | -US$21.73M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.